Can I read Managing HR+ HER2- Early Breast Cancer on EtoBox?

Managing HR+ HER2- Early Breast Cancer by vernadskyi is a document available to read on EtoBox.

What is Managing HR+ HER2- Early Breast Cancer about?

This document discusses the management of HR-positive/HER2-negative early breast cancer patients at risk of recurrence. It reviews factors used to assess recurrence risk such as tumor features, biomarkers like ER, PR, Ki-67, and gene expression profiling. Current guidelines recommend adjuvant endocrine therapy with tamoxifen or aromatase inhibitors for 5 years, and consider extending duration or adding targeted therapies like CDK4/6 or PARP inhibitors for high-risk patients. Ovarian suppression added to exe

Author

vernadskyi

Language

EN